Compare INSP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | STOK |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2018 | 2019 |
| Metric | INSP | STOK |
|---|---|---|
| Price | $56.42 | $33.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $94.00 | $39.20 |
| AVG Volume (30 Days) | ★ 894.4K | 648.1K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | 92.73 |
| EPS | ★ 4.89 | N/A |
| Revenue | $82,050,000.00 | ★ $184,420,000.00 |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $8.11 | $77.49 |
| P/E Ratio | $11.46 | ★ N/A |
| Revenue Growth | 62.18 | ★ 404.50 |
| 52 Week Low | $48.30 | $8.30 |
| 52 Week High | $163.35 | $40.22 |
| Indicator | INSP | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 45.21 |
| Support Level | $53.11 | $32.70 |
| Resistance Level | $60.15 | $35.06 |
| Average True Range (ATR) | 3.19 | 1.60 |
| MACD | 0.52 | -0.06 |
| Stochastic Oscillator | 69.66 | 31.16 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.